LIDDS has started four internal projects that focus on assessing the feasibility of using the NanoZolid® drug delivery technology for local or intratumoral immunotherapy.
These feasibility studies will investigate if four different immunomodulatory agents can be formulated with the NanoZolid drug delivery technology. The studies include biophysical and pharmacological characterization as well as studies in relevant disease models. The objective is to demonstrate that the NanoZolid drug delivery technology can be leveraged to develop novel immunotherapies that can act locally or intratumorally. A locally delivered immunotherapy has the potential to act either as a monotherapy or in combination with systemic immunotherapies e.g. checkpoint inhibitors. A successful combination treatment could significantly increase the response rates and efficacy rates of current immunotherapies.
Results from these preclinical feasibility studies are expected in the first and second quarter of 2018.
Immunotherapy for the treatment of cancer aims to activate and utilize the body’s own immune system to recognize and attack tumors and cancer cells and is today the fastest growing and most promising area of cancer research.
For more information, please contact:
Monica Wallter, CEO, +46 (0)737 07 09 22, email@example.com
LIDDS is required to disclose the information in this press release under the European Union’s Market Abuse Regulation and the Securities Market Act. The information was submitted through the agency of the aforementioned contact person for publication on 24 November 2017 at 08.30 CET.
LIDDS AB (publ) develops effective medications for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and efficiently, which means significantly fewer side effects and treatments compared with systemic treatment. NanoZolid technology allows for the controlled, long-term and adjusted release of the medication for up to six months. NanoZolid can be combined with both large and small pharmaceutical molecules. The company’s most advanced project is the prostate cancer product Liproca® Depot, which contains 2-hydroxyflutamide, which confirms that the technology has a documented clinical effect. The prostate cancer project is currently in Phase IIb. Industrial-scale production is taking place in collaboration with Recipharm. LIDDS has active development projects where NanoZolid is combined with antiandrogens, cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq, First North. Redeye AB is a certified adviser to LIDDS. For more information, go to www.liddspharma.com.